Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388992 | 0.75 | KCNN4 (0.60) | KCNN4KCNA3LMNATP53SMN1; SMN2 | |
| SCHEMBL332281 | 0.69 | KCNN4 (0.56) | KCNN4KCNA3LMNATP53SMN1; SMN2 | |
| SCHEMBL6864172 | 0.68 | POLB (0.40) | LMNASMN1; SMN2KMT2AL3MBTL1HTT | |
| SCHEMBL16965740 | 0.68 | KCNN4 (0.58) | KCNN4KCNA3LMNATP53SMN1; SMN2 | |
| SCHEMBL5479925 | 0.67 | CYP19A1 (0.66) | KCNN4KCNA3LMNATP53SMN1; SMN2 | |
| SCHEMBL16830121 | 0.67 | KCNN4 (0.50) | KCNN4KCNA3LMNATP53SMN1; SMN2 | |
| SCHEMBL16965405 | 0.66 | KCNN4 (0.56) | KCNN4KCNA3LMNATP53SMN1; SMN2 | |
| SCHEMBL6735303 | 0.65 | KCNN4 (0.42) | KCNN4KCNA3LMNATP53SMN1; SMN2 | |
| SCHEMBL41130 | 0.65 | KCNN4 (1.00) | KCNN4KCNA3LMNATP53SMN1; SMN2 | |
| SCHEMBL29499525 | 0.65 | KCNN4 (1.00) | KCNN4KCNA3LMNATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128584-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS INCORPORATED | 2021-05-06 | — | — | US | claimed |
| EP-3607942-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | University of Sheffield (GB) | 2020-02-12 | — | — | EP | claimed |
| US-20160067264-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | UNIVERSITY OF SHEFFIELD (GB) | 2016-03-10 | — | — | US | claimed |
| US-20140170768-A1 | METHOD FOR MONITORING AND ASSESSING PITUITARY FUNCTION | I-CALQ LLC | 2014-06-19 | — | — | US | claimed |
| US-20140005158-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS, INC. (US) | 2014-01-02 | — | — | US | claimed |
| EP-2532350-A1 | Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome | Laboratoire HRA Pharma (FR) | 2012-12-12 | — | — | EP | claimed |
| US-20110224179-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | UNIVERSITY OF SHEFFIELD (GB) | 2011-09-15 | — | — | US | claimed |
| EP-2364146-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | The University Of Sheffield (GB) | 2011-09-14 | — | — | EP | claimed |
| US-20110166115-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | US | claimed |
| EP-2306830-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Corcept Therapeutics, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2009050136-A2 | GLUCOCORTICOID RECEPTOR ANTAGONISTS SUCH AS MIFEPRISTONE FOR TREATING CUSHING' S SYNDROME | LABORATOIRE HRA PHARMA (FR) | 2009-04-23 | — | — | WO | claimed |
| EP-2012796-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | Corcept Therapeutics, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007131041-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CORCEPT THERAPEUTICS, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20020065259-A1 | Glucocorticoid blocking agents for increasing blood-brain barrier permeability | BIOPHARMA SECURED DEBT FUND II SUB, S.AR.L (LU) | 2002-05-30 | — | — | US | claimed |
| WO-2002040018-A1 | TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | ALCON, INC. (CH) | 2002-05-23 | — | — | WO | claimed |
| WO-2002017930-A2 | GLUCOCORTICOID BLOCKING AGENTS FOR INCREASING BLOOD-BRAIN BARRIER PERMEABILITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2002-03-07 | — | — | WO | claimed |
| US-6177427-B1 | NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. | 2001-01-23 | — | — | US | claimed |
| EP-1047410-A1 | TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. (US) | 2000-11-02 | — | — | EP | claimed |
| US-6051573-A | Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists | ALCON LABORATORIES, INC. (US) | 2000-04-18 | — | — | US | claimed |
| WO-1999032101-A1 | TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166115-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CRHR1, NR3C1, CRH | KCNN4 3627/4885KCNA3 3777/4885LMNA 1279/4885 |
| US-20110224179-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | CRH, SHBG, MC2R | KCNN4 1135/4885KCNA3 3623/4885LMNA 3004/4885 |
| US-20160067264-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | CRH, SHBG, MC2R | KCNN4 1325/4885KCNA3 3392/4885LMNA 3015/4885 |
| US-20140005158-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CRHR1, NR3C1, CRH | KCNN4 3627/4885KCNA3 3777/4885LMNA 1279/4885 |
| US-20210128584-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NR3C1, CRHR1, NR3C2 | KCNN4 3163/4885KCNA3 3710/4885LMNA 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.